

Prostatype Genomics receives breakthrough order from leading Italian urology centre valued at SEK 1.3 million

Prostatype Genomics AB (“Prostatype Genomics” or the “Company”) announces that the Company has received its largest order so far, valued at SEK 1.3 million, from University Hospital Policlinico Tor Vergata in Rome, Italy. The order comprises a low three-digit number of test kits for Prostatype®, the Company's prognostic gene test used for diagnosed prostate cancer. The hospital laboratory where the tests will be analysed has been validated by the Company, which means that testing of Italian patients can be initiated shortly.

With this order, Prostatype Genomics deepens its collaboration with Professor Pierluigi Bove, a leading Italian urologist with more than 150 published scientific articles, and with Giuseppe Novelli, Professor in medical genetics with approx. 700 published scientific articles. The University Hospital Policlinico Tor Vergata in Rome is a leading Italian urology centre which handles a significant number of new cases of prostate cancer in Italy each year.

“It feels great that we, together with Professor Bove and Professor Novelli, now will start the clinical use of Prostatype® in Italy, one of the largest and most influential markets in Europe. Professor Bove is at the forefront of urology care, using among other things minimally invasive surgery, and with Professor Novelli's vast knowledge and experience within the genetic field, their respective specialist knowledge makes for a perfect combination. Both Professor Bove and Professor Novelli are of course excellent ambassadors for Prostatype®,” says Prostatype Genomics' CEO Fredrik Rickman.

“Prostatype Genomics main focus is the US market, while selected European markets has and will be pursued on an ongoing basis. Italy is such a market with an attractive potential. The number of newly diagnosed patients with prostate cancer amounts to approx. 40.000 per year in Italy. The total number of Italian patients diagnosed with prostate cancer amounts to approx. 150.000, so we will be able to assist patients, physicians, and the healthcare system in Italy in a very positive way through this collaboration,” says Fredrik Rickman.

“Professor Bove and Professor Novelli both have an excellent reputation in Italy as well as internationally, and we are convinced that this very encouraging announcement will create a ripple effect both in Italy and throughout Europe. Prostatype Genomics estimates that the addressable market for Prostatype® in Italy amounts to over 100 MSEK annually,” Fredrik Rickman concludes.

For more information, please contact:

Fredrik Rickman, CEO Prostatype Genomics AB

Telephone: +46 (0)73 049 77 01

Email: fredrik.rickman@prostatypegenomics.com

About Prostatype Genomics AB

Prostatype® is a genomic test that is available to patients and treating urologists as a complementary decision basis for the question of treatment or no-treatment of prostate cancer. The test was developed by a leading research group at Karolinska Institute and is provided by Prostatype Genomics AB.

This information is information that Prostatype Genomics is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-12-03 08:30 CET.